The Power and Potential of Doxorubicin‐DNA Adducts

@article{Cutts2005ThePA,
  title={The Power and Potential of Doxorubicin‐DNA Adducts},
  author={Suzanne M. Cutts and Abraham Nudelman and Ada Rephaeli and Don R. Phillips},
  journal={IUBMB Life},
  year={2005},
  volume={57}
}
Doxorubicin (trade name Adriamycin) is a widely used anticancer agent which exhibits good activity against a wide range of tumors. Although the major mode of action appears to be normally as a topoisomerase II poison, it also exhibits a number of other cellular responses, one of which is the ability to form adducts with DNA. For adduct formation doxorubicin must react with cellular formaldehyde to form an activated Schiff base which is then able to form an aminal (N‐C‐N) linkage to the… 
Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.
TLDR
It is shown that doxorubicin-DNA adducts induce a more cytotoxic response in HL-60 cells than doxorbicin as a single agent, and that theseAdducts are more cytOToxic than topoisomerase II-mediated lesions.
Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate
TLDR
Although apoptosis assays indicated a greater than additive effect for epirubicin/AN-9 combinations, this effect was much more pronounced for doxorubic in/AN -9 combinations.
Barminomycin, a model for the development of new anthracyclines.
TLDR
The enhanced stability of barminomycin-DNA adducts appears to be due primarily to protection of the aminal linkage from hydrolysis and this has provided insight into the design of new anthracycline derivatives with enhanced stability and activity.
Anthracycline-formaldehyde conjugates and their targeted prodrugs.
TLDR
The sequence of research leading to a proposal for anthracycline cross-linking of DNA is presented and a promisinglead design is pentyl PABC-Doxaz, targeted to aÂcarboxylesterase enzyme overexpressed in liver cancercells and/or colon cancer cells.
Analysis of cross-linking between DNA and anthracyclines
TLDR
This work established that nemorubicin is converted by enzyme CYP3A in a more cytotoxic metabolite PNU-159682, which was found to be 700-2400 times more potent that its parent drug toward cultured human cancer cells and which exhibits significant efficacy in in vivo tumor models.
Analysis of covalent ellipticine- and doxorubicin-derived adducts in DNA of neuroblastoma cells by the ³²P-postlabeling technique.
TLDR
The results suggest that covalent binding of ellipticine to DNA of UKF-NB-3 and UKF -NB-4 neuroblastoma cell lines is the predominant mechanism responsible for the cytotoxicity of this drug.
IS METABOLIC ACTIVATION OF TOPOISOMERASE II POISONS IMPORTANT IN THE MECHANISM OF CYTOTOXICITY?
TLDR
In this review, the significance of metabolic activation of doxorubicin and etoposide in the mechanism of tumor cytotoxicity is critically evaluated.
Stability and iron coordination in DNA adducts of Anthracycline based anti-cancer drugs.
TLDR
Iron is found to coordinate well to the drugs containing an α-ketol group, this being the only group of the drug that binds to the metal, which may result in higher hydroxyl radical production, thus explaining the increased cardiotoxicity noted for Doxorubicin.
...
...

References

SHOWING 1-10 OF 53 REFERENCES
Sequence specificity of adriamycin-DNA adducts in human tumor cells.
TLDR
It is shown that when Adriamycin is used in conjunction with the formaldehyde-releasing prodrug AN-9 in IMR-32 tumor cells, this allows the formation of sufficiently high levels of adducts in genomic DNA to enable detection of their DNA sequence specificity for the first time.
Redox pathway leading to the alkylation of DNA by the anthracycline, antitumor drugs adriamycin and daunomycin.
TLDR
The results suggest a pathway to the inhibition of transcription by reductively activated adriamycin and daunomycin and the proposed molecular structure is duplex DNA containing two molecules of anthracycline bound to a separate strand of the DNA via a methylene group.
Characterization of covalent adriamycin-DNA adducts.
TLDR
It is shown by homo- and heteronuclear NMR spectroscopy that the covalent Adriamycin-DNA adduct is structurally equivalent to that resulting from direct reaction with formaldehyde.
Formaldehyde-releasing prodrugs in combination with adriamycin can overcome cellular drug resistance.
TLDR
Changing the mechanism via which Adriamycin exerts its anticancer effect by dramatically increasing adduct levels (requiring coadministration of formaldehyde-releasing prodrugs) may be a useful means of cancer treatment, as well as for overcoming Adri amycin-induced resistance.
Structural requirements for the formation of anthracycline-DNA adducts.
TLDR
The DNA sequence specificity of all anthracyclines was similar, although barminomycin was the most selective for 5'-GC, and barmineomycin adducts were the most stable at 37 degrees C while carminomycins II and III lesions were least stable.
Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells.
TLDR
The design and 11-step synthesis of doxorubicin-formaldehyde conjugates targeted to the estrogen receptor, which is commonly overexpressed in breast cancer cells, are reported.
Doxorubicin-formaldehyde conjugate, doxoform: induction of apoptosis relative to doxorubicin.
TLDR
The similar behavior of DOXF and DOX supports the role of formaldehyde in the cytotoxic mechanism of the clinical anthracycline antitumor agents and provides further support for the proposition thatDOXF is a prodrug to the DOX active metabolite.
Doxoform and Daunoform: anthracycline-formaldehyde conjugates toxic to resistant tumor cells.
TLDR
Daunoform reacts with the self-complementary deoxyoligonucleotide (GC)4 faster than the combination of daunorubicin and formaldehyde at an equivalent concentration to given drug-DNA adducts, and in spite of hydrolytic instability, Doxoform is 150-fold more toxic to MCF-7 human breast cancer cells and 10000-foldMore toxic toMCF- 7/ADR resistant cells.
Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9).
TLDR
The enhanced levels of these adducts and the accompanying decreased cell viability were directly related to the esterase-dependent release of formaldehyde from AN-9, providing evidence for the formaldehyde-mediated activation of Adriamycin.
...
...